Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419764 | PMC |
| http://dx.doi.org/10.1016/j.hrcr.2016.01.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in minimally invasive treatment of malignant obstructive jaundice.
World J Gastrointest Surg
December 2024
Department of Outpatient, Puer People's Hospital, Puer 665000, Yunnan Province, China.
Malignant obstructive jaundice (MOJ) encompasses a range of diseases stemming from malignant tumors such as cholangiocarcinoma, pancreatic cancer, and primary liver cancer, among others, which cause obstruction in both intra- and extra-hepatic bile ducts. This obstruction may lead to elevated bilirubin levels, hepatic function impairment, and a low rate of successful surgical resection in clinical settings. There are various minimally invasive treatment options for MOJ, including endoscopic biliary drainage, ultrasound-guided procedures, and percutaneous biliary tract puncture drainage.
View Article and Find Full Text PDFPercutaneous transhepatic cholangiography: An effective option for endo-biliary radiofrequency ablation before stent insertion in unresectable biliary cancer?
World J Clin Cases
October 2024
Academic Department of Gastroenterology, Medical School of the National and Kapodistrian University of Athens, "Laiko" General Hospital, Athens 11527, Greece.
Biliary cancer is a highly aggressive disease that is typically diagnosed at advanced stages when surgical removal is no longer an option. In these cases, palliative care and mechanical widening of the blocked biliary system are preferred. The insertion of a stent is often necessary to prevent the recurrence of blockages caused by cancer progression.
View Article and Find Full Text PDFOutcomes of percutaneous endobiliary radiofrequency ablation in managing resistant benign biliary strictures: a retrospective analysis.
Br J Radiol
January 2025
Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL 60611, United States.
Article Synopsis
- The study evaluated the safety and effectiveness of percutaneous endobiliary radiofrequency ablation (EB-RFA) for treating stubborn benign biliary strictures in 15 patients who had unsuccessful traditional treatments.
- Results showed a 100% technical success rate and an 87% clinical success rate after a median follow-up of 17 months, indicating significant improvement in patients’ conditions.
- The findings suggest that EB-RFA is a promising option for these strictures, though more extensive studies are needed for more conclusive evidence.
Objective: Meta-analysis was used to assess the efficacy and safety of ultrasound-guided radiofrequency ablation combined with transhepatic artery embolization chemotherapy for hepatocellular carcinoma.
Methods: Randomized controlled studies on ultrasound-guided radiofrequency ablation combined with transhepatic artery embolization chemotherapy for hepatocellular carcinoma were searched in the databases of PubMed, Embase, Cochrane library, web of science with a search deadline of March 14, 2024. Data were analyzed using Stata 15.
Combined Percutaneous Transhepatic Lymphatic Embolization and Peroral Duodenal Mucosal Radiofrequency Ablation to Manage Protein-Losing Enteropathy.
J Vasc Interv Radiol
September 2024
Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Chicago, Illinois. Electronic address:
Percutaneous transhepatic lymphatic embolization (PTLE) and peroral esophagogastroduodenoscopy (EGD) duodenal mucosal radiofrequency (RF) ablation were performed to manage protein-losing enteropathy (PLE) in patients with congenital heart disease. Five procedures were performed in 4 patients (3 men and 1 woman; median age, 49 years; range, 31-71 years). Transhepatic lymphangiography demonstrated abnormal periduodenal lymphatic channels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!